Back

Comparison of de-escalation of DAPT intensity or duration in East Asian and Western patients with ACS undergoing PCI: A systematic review and meta-analysis

26 August 2023 (10:24 - 10:33)
Organised by: Logo
Congress Presentation Part of: Optimal antithrombotic regimen after percutaneous coronary intervention in stable coronary artery disease Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Miss Rafaella I L Markides

University of Cambridge, Cambridge (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Ticagrelor or Clopidogrel to reduce ischemic events after Percutaneous Coronary Intervention in chronic coronary syndrome in clopidogrel naive patient: the ALPHEUS Naive sub-study.
Professor J. Silvain (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Clopidogrel vs. aspirin in the chronic maintenance period following percutaneous coronary intervention in high thrombotic and high bleeding risk patients:sub-analysis of the HOST-EXAM Extended study
Doctor J. Chung (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Ticagrelor versus clopidogrel for complex percutaneous coronary intervention in chronic coronary syndrome: a post-hoc analysis of the ALPHEUS study
Professor B. Lattuca (Nimes, FR)
Abstract Slides Video
Presentation thumbnail
Meta-analysis of 3-month vs 12-month dual anti-platelet therapy after percutaneous coronary intervention
Doctor F. Gerardo (Amadora, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Optimal antithrombotic regimen after percutaneous coronary intervention in stable coronary artery disease
Video

The Event

Event poster

ESC Congress 2023

26 August 2023 10:24 CET
You may be interested in
thumbnail
Congress Presentation
A shorter duration of dual-antiplatelet therapy following percutaneous coronary intervention by region of study: a meta-analysis of randomized clinical trials
thumbnail
Congress Presentation
Reducing intensity of dual antiplatelet therapy in acute coronary syndromes: what is the optimal timing?
thumbnail
Congress Presentation
Dual antiplatelet therapy de-escalation or abbreviation: if I had to choose one of them

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources